NSW is on track to virtually eliminate HIV transmission by 2020 as an expanded PrEP trial, led by the Kirby Institute at UNSW, enrols its one thousandth participant in record time.
The Kirby Institute at UNSW has welcomed the Therapeutic Goods Administration's approval of antiretroviral drug Truvada as pre-exposure prophylaxis (PrEP) in Australia.
